Link to this page
National Cancer Institute Thesaurus
Last uploaded:
July 2, 2026
| Id | http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C71532
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C71532
|
|---|---|
| Preferred Name | Lonaprisan |
| Definitions |
An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B.
|
| Synonyms |
Progesterone Receptor Antagonist ZK 230211
11 beta-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17 alpha-pregna-5,9-dien-3-one
BAY86-5044
LONAPRISAN
Lonaprisan
ZK 230211
ZK-PRA
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label | Lonaprisan
|
|---|---|
| prefixIRI | Thesaurus:C71532
|
| code | C71532
|
| DEFINITION | An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B.
|
| Legacy Concept Name | Progesterone-Receptor_Antagonist_ZK_230211
|
| PDQ_Open_Trial_Search_ID | 579241
|
| Contributing_Source | FDA
|
| Accepted_Therapeutic_Use_For | Treatment of progesterone receptor positive breast cancer
|
| PubMedID_Primary_Reference | 11150172
|
| NCI_Drug_Dictionary_ID | 579241
|
| FULL_SYN | Progesterone Receptor Antagonist ZK 230211
11 beta-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17 alpha-pregna-5,9-dien-3-one
BAY86-5044
LONAPRISAN
Lonaprisan
ZK 230211
ZK-PRA
See more
See less
|
| Chemical_Formula | C28H29F5O3
|
| UMLS_CUI | C2347691
|
| FDA_UNII_Code | F5Z5EL4D26
|
| Preferred_Name | Lonaprisan
|
| type | |
| subClassOf | |
| PDQ_Closed_Trial_Search_ID | 579241
|
| CAS_Registry | 211254-73-8
|
| Concept_In_Subset | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |